Please login to the form below
sitagliptin
This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.
Givlaari, Rybelsus lead crowded CHMP recommendations
In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved greater blood glucose reductions compared to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), Boehringer Ingelheim and Eli
Latest news
-
Merck CFO: we’re not only about Keytruda
shrug off a 12% decline for diabetes treatment Januvia (sitagliptin) on pricing pressure.
-
Novo Nordisk gets FDA okay for new diabetes hope
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's DPP-4 inhibitor Januvia(sitagliptin), Boehringer Ingelheim and Eli Lilly's SGLT2
-
Novo uses voucher for speedy answer on oral semaglutide
In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's Januvia (sitagliptin) Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) and
-
Analysts look beyond Keytruda in Merck’s future
Chief executive Ken Frazier took pains to point to other growth spots in MSD’s portfolio, particularly as diabetes blockbuster Januvia (sitagliptin) showed signs of weakness again after a return to
-
Reference price bill tabled in US House and Senate
savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens), Merck &Co’s Januvia (sitagliptin) for diabetes, and Astellas/Pfizer’s prostate cancer therapy Xtandi (enzalutamide).
Merck CFO: we’re not only about Keytruda
Novo Nordisk gets FDA okay for new diabetes hope
Analysts look beyond Keytruda in Merck’s future
Reference price bill tabled in US House and Senate
More from news
Approximately 8 fully matching, plus 88 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
-
Interview: Christopher Boulton, AstraZeneca
sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.
Market dynamics, marketing and analytics
Interview: Christopher Boulton, AstraZeneca
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
No results were found
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
